Protagonist Therapeutics, Inc.
PTGX
Rangering i aksjer
#2250
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to... Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Aksjekurs
$138.50
Sist synkronisert: 2026-10-20
Markedsverdi
$8.96B
Endring (1 dag)
3.02%
Endring (1 år)
84.67%
Land
US
Handel Protagonist Therapeutics, Inc. (PTGX)
Kategori
Healthcare
P/B-forhold for Protagonist Therapeutics, Inc. (PTGX)
P/B-forhold per October 2026 TTM: 10.68
Ifølge Protagonist Therapeutics, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 10.68. Ved slutten av 2023 hadde selskapet et P/B-forhold på 3.87.
P/B-historikk for Protagonist Therapeutics, Inc. fra 2014 til 2026
P/B-forhold ved hvert års slutt
| År | P/B-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 10.68 | 203.34% |
| 2024 | 3.52 | -8.97% |
| 2023 | 3.87 | -487.84% |
| 2022 | -1.00 | -74.24% |
| 2021 | -3.87 | 58.39% |
| 2020 | -2.44 | 191.32% |
| 2019 | -0.84 | -21.73% |
| 2018 | -1.07 | -70.44% |
| 2017 | -3.62 | 63.74% |
| 2016 | -2.21 | -130.85% |
| 2015 | 7.18 | -17.10% |
| 2014 | 8.66 | 0.00% |
P/B-forhold for lignende selskaper eller konkurrenter
| Selskap | P/B-forhold | Forskjell i P/B-forhold | Land |
|---|---|---|---|
| 6.251 | -41.46% |
US
|
|
| 13.2547 | 24.13% |
US
|
|
| 4.208 | -60.59% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -42.10% |
NL
|
